Simultaneous haploinsufficiency of Pten and Trp53 tumor suppressor genes accelerates tumorigenesis in a mouse model of prostate cancer.

[1]  A. Balmain,et al.  Promotion of Hras-induced squamous carcinomas by a polymorphic variant of the Patched gene in FVB mice , 2007, Nature.

[2]  R. DiPaola,et al.  Vitamin D Inhibits the Formation of Prostatic Intraepithelial Neoplasia in Nkx3.1; Pten Mutant Mice , 2006, Clinical Cancer Research.

[3]  W. Gerald,et al.  Combinatorial activities of Akt and B-Raf/Erk signaling in a mouse model of androgen-independent prostate cancer , 2006, Proceedings of the National Academy of Sciences.

[4]  Shunyou Wang,et al.  Pten deletion leads to the expansion of a prostatic stem/progenitor cell subpopulation and tumor initiation , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[5]  Robert D. Cardiff,et al.  Selective Evolution of Stromal Mesenchyme with p53 Loss in Response to Epithelial Tumorigenesis , 2005, Cell.

[6]  E. Tokunaga,et al.  Genetic mutual relationship between PTEN and p53 in gastric cancer. , 2005, Cancer letters.

[7]  Jason A. Koutcher,et al.  Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis , 2005, Nature.

[8]  Jingxia Li,et al.  Loss of tumor suppressor p53 decreases PTEN expression and enhances signaling pathways leading to activation of activator protein 1 and nuclear factor kappaB induced by UV radiation. , 2005, Cancer research.

[9]  P. Pandolfi,et al.  Genetic analysis of Pten and Tsc2 functional interactions in the mouse reveals asymmetrical haploinsufficiency in tumor suppression. , 2005, Genes & development.

[10]  A. Levine,et al.  The coordinate regulation of the p53 and mTOR pathways in cells. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[11]  T. Tsuruo.  Tumorigenesis facilitated by Pten deficiency in the skin: evidence of p53-Pten complex formation on the initiation phase. , 2005, Cancer Science.

[12]  M. Rubin,et al.  Prostate Pathology of Genetically Engineered Mice: Definitions and Classification. The Consensus Report from the Bar Harbor Meeting of the Mouse Models of Human Cancer Consortium Prostate Pathology Committee , 2004, Cancer Research.

[13]  A. Balmain,et al.  Genetic interactions between Pten and p53 in radiation-induced lymphoma development , 2003, Oncogene.

[14]  P. Pandolfi,et al.  Pten Dose Dictates Cancer Progression in the Prostate , 2003, PLoS biology.

[15]  Hua-Chuan Zheng,et al.  Role of PTEN and MMP‐7 expression in growth, invasion, metastasis and angiogenesis of gastric carcinoma , 2003, Pathology international.

[16]  P. Nelson,et al.  Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. , 2003, Cancer cell.

[17]  H. Hanafusa,et al.  PTEN Induces Cell Cycle Arrest by Decreasing the Level and Nuclear Localization of Cyclin D1 , 2003, Molecular and Cellular Biology.

[18]  Hong Wu,et al.  PTEN tumor suppressor regulates p53 protein levels and activity through phosphatase-dependent and -independent mechanisms. , 2003, Cancer cell.

[19]  Pier Paolo Pandolfi,et al.  PTEN and p53: who will get the upper hand? , 2003, Cancer cell.

[20]  Jose J. Galvez,et al.  Prostatic intraepithelial neoplasia in genetically engineered mice. , 2002, The American journal of pathology.

[21]  T. Liu,et al.  Promoter analysis of tumor suppressor gene PTEN: identification of minimum promoter region. , 2002, Biochemical and biophysical research communications.

[22]  R. Cardiff,et al.  Cooperativity of Nkx3.1 and Pten loss of function in a mouse model of prostate carcinogenesis , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[23]  J. Dixon,et al.  PTEN Protects p53 from Mdm2 and Sensitizes Cancer Cells to Chemotherapy* , 2002, The Journal of Biological Chemistry.

[24]  M. Ittmann,et al.  Haploinsufficiency of the Pten tumor suppressor gene promotes prostate cancer progression , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[25]  T. Mak,et al.  Regulation of PTEN transcription by p53. , 2001, Molecular cell.

[26]  R. Mamillapalli,et al.  PTEN regulates the ubiquitin-dependent degradation of the CDK inhibitor p27KIP1 through the ubiquitin E3 ligase SCFSKP2 , 2001, Current Biology.

[27]  P. Pandolfi,et al.  Pten and p27KIP1 cooperate in prostate cancer tumor suppression in the mouse , 2001, Nature Genetics.

[28]  J. Gustafsson,et al.  Evidence that epithelial and mesenchymal estrogen receptor-alpha mediates effects of estrogen on prostatic epithelium. , 2001, Developmental biology.

[29]  R. Cardiff,et al.  Sex hormone-induced carcinogenesis in Rb-deficient prostate tissue. , 2000, Cancer research.

[30]  T. Mak,et al.  High incidence of breast and endometrial neoplasia resembling human Cowden syndrome in pten+/- mice. , 2000, Cancer research.

[31]  Jerilyn A. Walker,et al.  Preparation of PCR-quality mouse genomic DNA with hot sodium hydroxide and tris (HotSHOT). , 2000, BioTechniques.

[32]  Domenico Coppola,et al.  Frequent activation of AKT2 and induction of apoptosis by inhibition of phosphoinositide-3-OH kinase/Akt pathway in human ovarian cancer , 2000, Oncogene.

[33]  H. Wu,et al.  PTEN modulates cell cycle progression and cell survival by regulating phosphatidylinositol 3,4,5,-trisphosphate and Akt/protein kinase B signaling pathway. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[34]  A. Costa-Pereira,et al.  Molecular and cellular biology of prostate cancer—the role of apoptosis as a target for therapy , 1999, Prostate Cancer and Prostatic Diseases.

[35]  C. Cordon-Cardo,et al.  Mutation of Pten/Mmac1 in mice causes neoplasia in multiple organ systems. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[36]  Hong Sun,et al.  PTEN/MMAC1/TEP1 suppresses the tumorigenicity and induces G1 cell cycle arrest in human glioblastoma cells. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[37]  A. Deitch,et al.  Very frequent p53 mutations in metastatic prostate carcinoma and in matched primary tumors , 1998, Cancer.

[38]  Carlos Cordon-Cardo,et al.  Pten is essential for embryonic development and tumour suppression , 1998, Nature Genetics.

[39]  M. Ittmann,et al.  Homozygous deletion of the PTEN tumor suppressor gene in a subset of prostate adenocarcinomas. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[40]  W. Isaacs,et al.  Interfocal heterogeneity of PTEN/MMAC1 gene alterations in multiple metastatic prostate cancer tissues. , 1998, Cancer research.

[41]  J. Herman,et al.  Frequent inactivation of PTEN/MMAC1 in primary prostate cancer. , 1997, Cancer research.

[42]  W. Isaacs,et al.  Relation between aberrant α‐catenin expression and loss of E‐cadherin function in prostate cancer , 1997, International journal of cancer.

[43]  M. Wigler,et al.  PTEN, a Putative Protein Tyrosine Phosphatase Gene Mutated in Human Brain, Breast, and Prostate Cancer , 1997, Science.

[44]  G. Cunha,et al.  Induction of prostatic morphology and secretion in urothelium by seminal vesicle mesenchyme. , 1995, Development.

[45]  W. Isaacs,et al.  Decreased E-cadherin expression is associated with poor prognosis in patients with prostate cancer. , 1994, Cancer research.

[46]  R. deVere White,et al.  p53 in prostate cancer: frequent expressed transition mutations. , 1994, Journal of the National Cancer Institute.

[47]  S. Hilsenbeck,et al.  p53 is mutated in a subset of advanced-stage prostate cancers. , 1993, Cancer research.

[48]  W. Isaacs,et al.  Expression of the cellular adhesion molecule E-cadherin is reduced or absent in high-grade prostate cancer. , 1992, Cancer research.

[49]  G. Cunha,et al.  Morphological and histological study of castration-induced degeneration and androgen-induced regeneration in the mouse prostate. , 1986, Biology of reproduction.

[50]  R. Cardiff,et al.  Dissociation of epithelial and neuroendocrine carcinoma lineages in the transgenic adenocarcinoma of mouse prostate model of prostate cancer. , 2008, The American journal of pathology.

[51]  E. Gelmann,et al.  p53 abnormalities in primary prostate cancer: single-strand conformation polymorphism analysis of complementary DNA in comparison with genomic DNA. The Cooperative Prostate Network. , 1997, Journal of the National Cancer Institute.

[52]  R. Bookstein.  Tumor suppressor genes in prostatic oncogenesis. , 1994, Journal of cellular biochemistry. Supplement.

[53]  G. Cunha,et al.  Mesenchymal-epithelial interactions: technical considerations. , 1987, Progress in clinical and biological research.